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Background: TG4010 is a recombinant viral vector expressing both
the tumor-associated antigen MUC1 and Interleukine-2. This vector
is based on the modified virus of Ankara, a significantly attenuated
strain of vaccinia virus. TG4010 has been designed to induce or
amplify a cellular immune response directed against tumor cells
expressing MUC1.
Methods: A multicenter, randomized phase II study has explored
two schedules of the combination of TG4010 with first line chemo-
therapy in patients with stage IIIB/IV non-small cell lung cancer. In
Arm 1, TG4010 was combined upfront with cisplatin (100 mg/m2
day 1) and vinorelbine (25 mg/m2 day 1 and day 8). In Arm 2,
patients were treated with TG4010 monotherapy until disease pro-
gression, followed by TG4010 plus the same chemotherapy as in
Arm1. Response rate was evaluated according to RECIST. Median
time to progression and median overall survival were calculated
according to the Kaplan–Meier method.
Results: Sixty-five patients were enrolled, 44 in Arm 1 and 21 in
Arm 2, in accordance with the two stage Simon design of the
statistical plan. In Arm 1, partial response was observed in 13
patients out of 37 evaluable patients (29.5% of the intent to treat
population, 35.1% of the evaluable patients). In Arm 2, two patients
experienced stable disease for more than 6 months with TG4010
alone (up to 211 days), in the subsequent combination with chemo-
therapy, one complete and one partial response were observed out of
14 evaluable patients. Arm 2 did not meet the criteria for moving
forward to second stage. The median time to progression was 4.8
months for Arm 1. The median overall survival was 12.7 months for
Arm 1 and 14.9 for Arm 2. One year survival rate was 53% for Arm
1 and 60% for Arm 2. TG4010 was well tolerated, mild to moderate
injection site reactions, flu-like symptoms, and fatigue being the
most frequent adverse reactions. A MUC1-specific cellular immune
response was observed in lymphocyte samples from all responding
patients evaluable for immunology.
Conclusions: The combination of TG4010 with standard chemo-
therapy in advanced non-small cell lung cancer is feasible and shows
encouraging results. A randomized study evaluating the addition of
TG4010 to first line chemotherapy in this population is in progress.
Key Words: Phase II study, Recombinant viral vector, Chemother-
apy, Non-small cell lung cancer, Vaccine, MUC1, MVA.
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Lung cancer is the leading cause of cancer related mortalityin both men and women. The majority of new cases of
lung cancer are non-small cell lung cancer (NSCLC). About
60% of cases are diagnosed as unresectable or advanced. In
patients with unresectable localized NSCLC chemotherapy
combined with radiation is a validated option. For patients
with advanced or metastatic NSCLC, the usual treatment
option is palliative chemotherapy which has demonstrated a
positive impact on survival but, clearly, the treatment of these
patients remains unsatisfactory, and more effective therapies
needs to be developed.1 Targeted therapies and immunother-
apy are innovative approaches with the potential of improv-
ing the treatment of patients with advanced NSCLC. Most
advanced targeted therapies based on either small inhibitory
molecules or monoclonal antibodies interfere with tumor
growth, angiogenesis, or both.2 Immunotherapy is based
mainly on therapeutic vaccinations designed to induce or
amplify an immune response directed against the population
of tumor cells.3 A potential target for immunotherapy of lung
cancer is the tumor-associated antigen, MUC1.4 The MUC1
protein is a highly glycosylated mucin (MW 200 kD),
normally found at the apical surface of mucin-secreting
epithelial cells in many types of tissue, including the breast,
prostate, lungs, pancreas, stomach, ovaries, fallopian tubes,
intestine, and kidney5,6 Cancer in secretory epithelial cells is
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often accompanied by excess expression of MUC1 by the
tumor cells 7–9 and an aberrant glycosylation, revealing new
peptide and carbohydrate epitopes.10 TG4010 is a specific
immunotherapy product targeting the tumor associated
MUC1 antigen. It consists of a viral suspension of a modified
virus of Ankara (MVA) containing the sequences coding for
the human MUC1 protein and for the human interleukin-2
(IL2). The MVA is a vaccinia virus which belongs to the
poxvirus family. This strain is significantly attenuated and
was specifically developed to immunize patients at high risk
for complication of vaccination against smallpox with classic
strains.11,12 TG4010 was developed for use in cancer patients
whose tumors express the MUC1 antigen.13 Two phase I dose
escalation bridging studies have been completed with
TG4010. The dose of 108 plaque forming units (pfu) per
injection was considered a maximal feasible dose, regarding
the volume and concentration, but not the maximal tolerated
dose. Three patients had a metastatic NSCLC and in one of
them multiple metastases shrank with a 2 months delay after
the last vaccination.14 The safety profile and the early signs of
clinical and biologic activity served as a basis for a phase II
program of TG4010 in several indications. The purpose of the
present study was to assess whether the clinical activity of
TG4010 in patients with NSCLC is sufficient to justify
further clinical development, by evaluating the effects of
vaccination (TG4010) in combination with chemotherapy.
PATIENTS AND METHODS
Study Population
Patients were enrolled according to the following cri-
teria: histologically confirmed non-small cell carcinoma of
the lung with documentation of MUC1 antigen expression
on the primary tumor or on metastasis by a positive staining
with the H23 monoclonal antibody15 stage IIIB or IV
NSCLC, with no prior treatment for advanced disease; at
least one measurable lesion according to RECIST; ECOG
Performance status 0 or 1; age more than 18; adequate
hematological, hepatic, and renal function; written informed
consent from the patient. Patients presenting one of the
following criteria were excluded from the study: history of
any form of systemic therapy for non-small cell carcinoma of
the lung except for neoadjuvant treatment; uncontrolled brain
metastases, prior history of other malignancy except for
nonmelanoma skin cancer or other cured cancer for more than
5 years; any other serious concomitant systemic medical
disorder incompatible with participation in the study; previ-
ous (within 4 weeks before baseline) or concomitant systemic
steroids, immunosuppressive/immunomodulating drugs; pos-
itive serology for HIV, hepatitis B or C virus; pregnancy at
the entry or breast-feeding women, patient without adequate
protection against pregnancy during the conduct of the trial
and for 3 months after the last injection; allergy to eggs;
patients unable or unwilling to comply with protocol require-
ments.
Study Design
This was a randomized, open label, multicenter study
testing 108 pfu (plaque-forming units) of TG4010 either
in immediate combination with cytotoxic chemotherapy (vi-
norelbine-cisplatin) (Arm 1) or in monotherapy followed by
combination with the same chemotherapy at progression
(Arm 2).
Tumor response according to RECIST16 was the pri-
mary end point of the study and was evaluated every 6 weeks.
The tumor response taken into account was, for each patient,
the best overall response obtained during the study and
assessed by central reading. Stabilizations had to be main-
tained at least 12 weeks. Secondary endpoints were: safety of
the product alone and in combination with chemotherapy,
time to progression, survival, and cellular immune response
against MUC1 (CD4 or CD8). Upon satisfaction of all of
the inclusion and exclusion criteria, including obtaining writ-
ten, informed consent, patients had baseline status completed,
and were randomized into one of the two treatment Arms.
The intent to treat (ITT) population was defined in the
statistical analysis plan as the population of patients who
were randomized and received at least one administration
of the test product TG4010. The study was conducted in
accordance with the ethical principles in the Declaration of
Helsinki.
Treatment
In Arm 1, patients received up to 6 cycles, of 3 weeks
each, of vinorelbine (25 mg/m2 day 1–day 8)/cisplatin (100
mg/m2 day 1) in addition to subcutaneous (SC) injections of
TG4010 at the dose of 108 pfu, once every week for 6 weeks
then once every 3 weeks, TG4010 was administered the same
day as chemotherapy. Patients with complete response, par-
tial response (PR), or stable disease after chemotherapy were
treated until documentation of progressive disease (PD) with
TG4010 as a maintenance therapy.
In Arm 2, patients received TG4010 alone, SC injec-
tions at the dose of 108 pfu, once every week for 6 weeks then
once every 3 weeks, until documentation of PD. In case of
progression, they were treated with chemotherapy in addition
to TG4010, at the same regimen than in Arm 1, i.e., with up
to 6 cycles, of 3 weeks each, of vinorelbine/cisplatin. After
chemotherapy, if appropriate, they received TG4010 alone,
once every 3 weeks, until disease progression. To avoid a
possible interaction with the immune system, steroids, and
other immunosuppressive drugs were not allowed during
study. According to standard practice of each investigational
center, chemotherapy was delayed by 1 week each time the
investigator assessed that recovery of adverse events (AE)
from previous cycle did not allow the administration of a new
cycle. In this case, all assessments planned on that day and all
following assessments were to be delayed by 1 week, includ-
ing the TG4010 injections. TG4010 was administered by SC
injection in a single injection, the volume of which depending
on the specifications of each lot was usually 0.3 or 0.4 ml.
Both before and after the study drug administration, the skin
at the site of injection was to be disinfected with alcohol.
Four injection sites were to be used: left and right arm, left
and right thigh, according to a rotation schedule. Patients
were to be monitored for one half hour after each study drug
injection. Regarding the Genetic Modified Organism use
(manipulation and patient administration) national regulatory
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requirements of each country in which the study was con-
ducted were to be applied.
Statistical Plan
To minimize the sample size, a “minimax 2 stage
design” for phase II was used.17 The study design required 36
evaluable patients for the first stage of the study (18 in each
Arm), and 15 additional evaluable patients for each arm
moving to the second stage. It was foreseen to replace
patients not evaluable for the response. The purpose of the
study was to reject the experimental treatment from further
study if it was considered truly ineffective, and to accept it for
further study if it was truly effective. The study design was
based on the following assumptions: the ineffectiveness cut-
off was chosen to be equal to 20% and the effectiveness
cutoff equal to 40%. Hence the hypotheses of interest were
H0: r  20% against HA: r  40%, where r is the response
rate (complete response plus PR according to RECIST),
the type I error rate (, probability of accepting an ineffective
treatment, a false positive outcome) was set to 5%, the type
II error rate (, probability of rejecting an effective treatment,
a false negative outcome) was set to 20%. Under these
assumptions, an optimal design consisted of the following 2
stages: 18 evaluable patients per arm were to be obtained, if
fewer than 5 responses were observed in a treatment arm it
was stopped and the drug regimen of that arm declared
ineffective, otherwise, patient enrollment continued to obtain
33 evaluable patients for this arm. If at least 11 responses
were observed, the drug regimen of that arm was declared
effective. Time to progression, duration of response and
survival time were to be estimated by the Kaplan–Meier
methods and plotted as curves.
Immune Response Analyses
Forty milliliters of blood were drawn into CPT tubes
(Cell Preparation Tubes with Sodium Heparin, Beckton Dick-
inson) from patients at baseline, before the first injection of
either TG4010 or chemotherapy; at day 43 (1 week after the
sixth TG4010 injection and before the seventh injection) and
on day 64 (3 weeks after the seventh injection). Blood was
transported within 48 hours to a central laboratory (Claude
Levy Laboratories, Paris) for Hypaque-ficol separation and
peripheral blood mononuclear cells (PBMC) were frozen and
stored in liquid nitrogen until used for immunology testing.
Technical difficulties at the cell freezing laboratory resulted
in loss of PBMC from half of the patients and therefore only
31 patients were evaluable for immune response.
MUC1-specific CD4 (T helper) cell responses were
assessed by T cell proliferation as described previously.18
Briefly, PBMC were seeded into 96 well, flat bottom plates in
triplicate, at 105 cells per well, in AIM V culture medium
(Life Technologies, Grand Island, New York) alone or in the
presence of test peptide (5 g/ml). Synthetic peptides used
(NeoMPS, Strasbourg, France) corresponded to 23 amino
acids each, from the human MUC1 sequence, overlapping by
5 amino acids. Peptides covering the sequence of the MUC1
variable number tandem repeat (VNTR) and the region from
the VNTR to the extracellular N-terminus of the MUC1
sequence were used. Positive control antigens include Ultra-
violet light inactivated MVA (105 or 106 pfu) viral particles
(Transgene, Strasbourg, France), tetanus toxoid (Staten Se-
rum Institute, Copenhagen) 20 g/ml and IL-2 (1000 IU/ml).
A 24 amino acid peptide corresponding to the murine MUC1
VNTR was used as a negative control. After 4 days of culture,
3H-thymidine (1 Ci/well) was added and cells were har-
vested onto glass fiber filter paper and counted by liquid
scintillation. Results are expressed as stimulation index, which
is calculated as: Experimental counts per minute (cpm) (with
peptide or antigen)/control cpm (medium only). A stimulation
index of 2 or more is considered to be a positive response.
The MUC1-specific CD8 (Cytotoxic T Lymphocyte)
cellular response was assessed by ELISpot assay as previ-
ously described.19 Briefly, 5  105 PBMC were cultured for
6 days with 20 g/ml short MUC1 peptides (below) or
positive control viral peptides, in RPMI medium supple-
mented with 10% fetal bovine serum. IL-2 (50 IU/ml was
added after 2 days of culture. After 6 days of culture, cells
were collected and assessed for interferon gamma secreting
cells by ELISpot using the kit from Diaclone (Besanc¸on,
France) and according to the manufacturer’s instructions.
Briefly, PBMC were harvested from the sensitization cultures
and plated at 105 cells per well, in triplicate, in the ELISpot
plates and cultured with MUC1 short peptides for 16 hours
then assessed for ELISpots using an automatic ELISpot
counter (Zeiss, Le Pecq, France). HLA binding MUC1 pep-
tides were identified by a cell binding assay as described
previously.20,21 HLA-A2 represents over 40% of the Cauca-
sian population and four 9 amino acid sequences from MUC1
which bind to HLA-A2 have been published. An HLA-
binding analysis of 9 amino acid peptides was undertaken and
peptides were found, which bind with moderate to high
affinity to the most common HLA types (HLA-A1, A2, A3,
A11, A24, B7, and B8). Fourteen such peptides, in addition to
the 4 published sequences were used to test CTL activity, by
ELISpot in PBMC from patients in this study (Table 1). Low
stringency criteria were used to declare an ELISpot response
positive: A response was said to be positive if there were at
least 5 spots per 105 PBMC and if the value was at least 1.5
times the background ELISpot.
Some peptides have been described elsewhere
(LLLLTVLTV and STAPPVHNV;22 ALGSTAPPV,
TLAPATEPA and FLSFHISNL;20 NLTISDVSV.23
RESULTS
Study Population
Between May 2002 and February 2004 65 patients were
recruited, randomized, and treated in 9 centers in Belgium,
France, Poland, and Switzerland. In Arm 1, immediate com-
bination of chemotherapy among the first 18 evaluable pa-
tients, 7 achieved an objective response, consequently the
accrual was continued in the second stage of the Simon plan
to obtain 33 evaluable patients. Forty-four patients entered
this arm of the study and 37 patients were evaluable for
response. Arm 2, TG4010 followed by combination therapy
upon progression, did not meet the criteria for moving to the
second stage of the Simon plan and therefore the recruitment
was stopped after 21 inclusions.
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Clinical Characteristics
Forty-five men (69.2%) and 20 women (30.8%) partic-
ipated in the study. All patients were of Caucasian ethnicity,
the mean age at study entry was 59. Forty-nine (75.4%) had
a performance status classified ECOG-1 and 16 (24.6%) a
performance status ECOG-0. At baseline the majority of
patients, 49 patients (75.4%) were metastatic (TNM stage
IV), the other 16 (24.6%) patients were TNM stage IIIB
(locally advanced). Twenty-two (33.8%) patients underwent
a surgical resection of their lung cancer before entering the
trial, 8 (12.3%) had a radiotherapy and 2 had a neoadjuvant
chemotherapy. The most frequent histologic subtype of
NSCLC was adenocarcinoma found in 31 (47.7%) patients
followed by squamous cell carcinoma in 14 (21.5%) and
other subtypes in 20 (30.8%) patients. In the majority of the
patients, 49 (75.4%), the immunohistochemistry for the
MUC1 antigen has been carried out on a primary tumor
sample, for the other patients this analysis has been done on
a biopsy sample from a metastasis. The staining intensity was
described as strong 3/3, in a majority of the patients 52
(80%), less intense 2/3 in 12 patients (18.5%), and faint 1/3
in one patient. A membrane staining was present in 42
patients (64.6%) and a cytoplasmic staining in 53 patients
(81.5%)(Table 2).
Efficacy
In Arm 1, among the first 33 patients evaluable for
response 13 achieved a PR, therefore the primary end point of
11 responding patients out of 33 defined in the statistical plan
was achieved and the product considered worth of further
development. The ITT response rate after central reading was
13/44 (29.5%) whereas the response rate of the evaluable
patients was 13/37 (35.1%). Twelve other patients, 27.3% of
TABLE 1. Sequences of the Peptides Used for Monitoring
the Cellular Immune Response According to Patient HLA
Haplotype
TABLE 2. Patients Characteristics
Arm 1 TG4010  Chemotherapy
Immediately
n  44







Median 58.5 61 59
Range 33–76 37–77 33–77
Performance status (ECOG)
0 10 (22.7) 6 (28.6) 16 (24.6)
1 34 (77.3) 15 (71.4) 49 (75.4)
Gender
Male 31 (70.5) 14 (66.7) 45 (69.2)
Female 13 (29.5) 7 (33.3) 20 (30.8)
Stage
IIIB 11 (25.0) 5 (23.8) 16 (24.6)
IV 33 (75.0) 16 (76.2) 49 (75.4)
Histological sub-type
Adenocarcinoma 20 (45.0) 11 (52.4) 31 (47.7)
Squamous cell carcinoma 8 (18.2) 6 (28.6) 14 (21.5)
Other 16 (36.4) 4 (19.0) 20 (30.8)
MUC1 antigen staining
Membrane staining 32 (72.7) 10 (47.6) 42 (64.6)
Cytoplasmic staining 33 (75%) 20 (95.2) 53 (81.5)
Staining intensity
Faint (1/3) 0 (0) 1 (4.8) 1 (1.5)
Less intense (2/3) 9 (20.5) 3 (14.3) 12 (18.5)
Strong (3/3) 35 (79.5) 17 (81.0) 52 (80.0)
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TABLE 3. Clinical and Immunological Responses by Patient





Baseline Day 43 Day 64
(ve) MUC1 (ve) MUC1 (ve) MUC1
A. Arm 1
205/001 IIIB 01, 29 08 PR
210/002 IV 02, 24 44, 62 PR
210/009 IV 32, 66 07, 41 PR       B7
400/002 IV 01, 02 08, 39 PR     A2
400/005 IIIB 01, 02 08, 27 PR    
401/005 IIIB 03, 32 07, 18 PR    B7
401/006 IV 02, 03 44, 62 PR       A2
401/010 IV 01, 31 35, 58 PR       A1
401/011 IV 02 07, 44 PR
402/004 IIIB 11, 25 07, 18 PR      A11
501/002 IV 02, 28 07, 35 PR
501/003 IV 01 38, 51 PR
205/003 IV 29 44, 61 SD
210/007 IIIB 02, 03 27, 44 SD     
401/003 IV 01, 25 08, 18 SD     A1
401/004 IV 02, 30 44, 62 SD     A2
401/009 IV 11, 24 13, 61 SD    
402/002 IIIB 03, 33 38, 58 SD    
402/007 IIIB 02, 28 18, 44 SD      A2
402/009 IV 03, 33 07, 14 SD      
501/005 IV 02 17 SD   A2
501/006 IV 02, 24 18 SD    
602/002 IV 02, 03 35, 60 SD
603/001 IV 24, 30 13, 57 SD   A24
205/006 IV 03, 29 07, 45 PD
209/002 IV PD
209/009 IV 03, 28 40, 51 PD
210/003 IV 02, 32 38, 63 PD
210/008 IIIB 03 07, 14 PD    
400/003 IV 02 51, 57 PD  
400/004 IV 25, 26 18, 41 PD
401/007 IV 02 44 PD
402/008 IIIB 03, 11 07, 35 PD    
402/001 IIIB 02, 74 50, 58 PD       A2
402/005 IV 01, 03 51, 52 PD      
402/006 IV 03, 33 14, 44 PD
402/004 IV 09, 24 37 PD
401/001 IV 01, 25 18, 57 NE
402/003 IIB 02 51, 62 NE
402/008 IV 26, 30 18, 52 NE
602/008 IV 03, 19 14, 51 NE
602/005 IV 03 07, 18 NE
603/002 IV 01, 28 08, 21 NE
B. Arm 2
501/001 IV 01, 26 38, 51 CR
602/001 IIIB 11, 26 38, 44 PR
205/002 IIIb 01 08, 57 SD
205/004 IIIb 01, 32 08, 49 SD      A1/B8
209/003 IV 02, 03 07, 14 SD
400/001 IV 02, 24 07, 44 SD    
(Continued)
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the ITT population, had their disease stabilized for 12 weeks
or more. Thus, 25 patients (56.8% of the ITT population and
67.6% of the evaluable patients) had either a response or a
stabilization of the disease. Seven patients of this arm were
not evaluable for response: 1 patient was in PR and 3 patients
were stable at D43 (first evaluation) but had no confirmation
at D85; 3 patients had an early progression before D43. In
Arm 2 no objective response was observed with the vaccine
alone but 2 patients remained stable more than 6 months.
Fourteen patients in this arm received the combination ther-
apy and were considered evaluable for response, 2 of them
achieved a response, one complete and one partial (Table 3).
Mean duration of response was 4.3 months in Arm 1.
The complete and PR observed in Arm 2 lasted respectively
4.2 and 3 months.
Nineteen patients, 17 in Arm 1 and 2 in Arm 2, stable
or responding after 6 cycles of chemotherapy continued to be
administered with TG4010 as a maintenance therapy for a
mean duration of 3 months (range, 1–13.5).
Median time to progression (ITT) was 4.8 months in
Arm1. In Arm 2, the determination of the time to progression
was limited by the smaller number of patients but was
estimated to be 1.4 months for the monotherapy phase with
TG4010 and 7.2 months when taking into account the com-
bination phase of TG4010 with chemotherapy (Figure 1).
Median overall survival (ITT) was 12.7 months in Arm 1,
14.9 months in Arm 2, and 13.7 months for the whole study
population (Figure 2). The 1 year survival rate was 53% in
Arm 1, 60% in Arm 2, and 57% for the whole study
population.
Safety
The safety population of the study consisted of 65
patients who received at least one injection of the study drug
TG4010. The median number of injections was 8 in Arm 1
and 9 in Arm 2 corresponding respectively to a median
duration of exposure to the study drug of 3 and 3.3 months.
The median number of chemotherapy cycles was 4 in Arm 1
and 3 in Arm 2. Sixty-three (96.9%) out of the 65 patients of
the safety population experienced at least one AE of which 48
(73.8%) had at least one severe adverse AE. Most frequent
AEs in this study were anemia (34 patients, 52.3%), nausea
(33 patients, 50.8%), vomiting (32 patients, 49.2%), fatigue
(30 patients, 46.2%), and neutropenia (21 patients, 32.3%).
Thirty 2 (49.2%) patients presented with a possibly or prob-
ably study drug related AE. One hundred and eight AE
related to TG4010 were recorded in 32 patients, 106 of them
FIGURE 1. Time to Progression for the whole study period
(ITT).
TABLE 3. (Continued)





Baseline Day 43 Day 64
(ve) MUC1 (ve) MUC1 (ve) MUC1
602/006 IV 19, 33 05, 51 SD      
205/005 IIIb 01, 31 08, 65 PD      - A1/B8
209/005 IV 10, 29 40, 44 PD
209/007 IIIb 02 44, 37 PD     
209/008 IV 02, 24 07, 18 PD    
210/005 IV 01, 02 08, 18 PD
602/003 IV 01, 01 08, 58 PD
602/007 IV 02, 32 07, 18 PD     A2/B7
602/009 IV 01 17 PD      
209/001 IV 10, 29 18, 35 NE
209/004 IV 01, 02 08, 16 NE
209/006 IV 24, 31 27, 44 NE
210/001 IV 02, 24 07, 35 NE
210/004 IV 24 18, 57 NE
401/002 IV 25, 30 18, 51 NE
For each patient is given the stage of the NSCLC at baseline (BL), their HLA A and B groups.
The clinical response (CR indicates complete response; PR, partial response; SD, stable disease; PD, progressive disease; NE, non evaluable for response), the positivity () or
negativity () against positive control and against MUC1 at 3 time-points (baseline, D43 and D85), in case of positivity the recognized ELISpot peptides are indicated.
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were of grade 1 or 2. Most frequent related AEs were fatigue
(in 9 patients, 13.8%), injection site reactions (in 9 patients,
13.8%), injection site pain (in 6 patients, 9.2%), and pyrexia
(in 6 patients, 9.2%) (Table 4). Other flu-like symptoms such
as arthralgia and myalgia are reported also but less fre-
quently. Two AEs were classified severe (grade 3/4) and
possibly/probably related, respectively one anemia and one
papular rash. Fifty serious adverse event, none of them
related to TG4010, were recorded in 33 (50.8%) patients and
23 (35.4%) patients were withdrawn from the study due to
AEs. Fifteen patients died during their participation in the
study, 11 from disease progression and 4 from other causes.
No death, according to the investigators, was related to the
study drug (Table 4).
Immunology
Blood samples from 31 patients were evaluable for
immune response. Cellular immune responses in PBMC were
measured by T cell proliferation (a measure of specific CD4
T cell response) and by ELISpot (a measure of specific CD8
T cell response) as described. The CD8 T cell population
contains the MHC class I-restricted cytotoxic T cells which
are considered to be necessary for the immune elimination of
cancer cells. Positive T cell proliferation responses (Stimu-
lation Indices 2.0) of PBMC cultured with MUC1 peptides
ranged from 2 to 18.4 (median), with the magnitude of response
increasing with treatment in 4 patients (all in Arm 1). There were
10 MUC1-specific T cell proliferative responses at baseline and
8 at either day 43 or day 64. MUC1-specific recognition by the
CD8 T cells was more informative. Because an in vitro
stimulation was required to reveal ELISpot responses to MUC1,
the ELISpot data must be considered qualitative only ( or )
indicating the presence or absence of MUC1-specific CD8 T
cells in the PBMC samples. There were equal number of
ELISpot positive tests in the prevaccination PBMC samples
(10/31) as there were from day 43 or day 64 (10/31) (Table 3).
This shows that some patients had an existing CTL response to
MUC1 before immunotherapy with TG4010. ELISpot re-
sponses, like the T cell proliferative responses, were weak and
transient in a majority of patients. PBMC from roughly half of
the patients in each Arm showed evidence of MUC1-specific
ELISpot reactivity (12/23 in Arm 1 and 3/8 in Arm 2). The
magnitudes of the responses were not significantly different
between study Arms (data not shown). Induced ELISpot re-
sponses (i.e., responses detected in the postbaseline samples but
not in the baseline samples) were detected in 4 of 12 ELISpot
responding patients in Arm1 and in 1 of 3 ELISpot responding
patients in Arm 2. This suggests that concurrent chemotherapy
had little if any impact on the generation of the cellular immune
response. In the ELISpot evaluable group of patients, 12/21
patients with disease control (PR or stable disease) had MUC1-
specific ELISpot responses at any time-point, whereas only 3/10
patients with PD had MUC1-specific ELISpot during the study.
At least in Arm 1 there was an association between MUC1
ELISpot at baseline and disease control. Regarding patients who
developed a MUC1 specific ELISpot response during the study
4 out of 5 enjoyed a disease control (Table 3).
In Figure 3, it can be seen that patients who had
detectable MUC1-specific ELISpot response (at any time-
point), had significantly longer time to progression (Figure
3A) and overall survival (Figure 3B).
These data suggest that a CD8 T cell response to
MUC1 is associated with a better outcome in NSCLC patients
in first line chemotherapy.
In previous clinical studies with either Vaccinia Virus-
MUC1-IL22425 and with MVA-MUC1-IL2 (TG4010)14 pa-
tient sera were tested at various timepoints for antibody
responses to the vector and to MUC1. Although antibody
responses to the vector were observed, no antibody responses
to MUC1 was seen. For this reason, antibody responses to
MUC1 were not assessed in this study.
DISCUSSION
Based on phase I observations with the product
TG4010 and on the fact that 60 to 70% of NSCLC express the
MUC1 antigen this phase II study was aimed to assess the
efficacy of TG4010 in this indication. Advanced stages have
been chosen because they represent the great majority of the
NSCLC suffering patients and because the medical need in
this setting is very high. Chemotherapy brings to these pa-
tients a clear but limited survival benefit and remains the
standard of care.1 The purpose of this study was to investigate
whether specific immunotherapy against a tumor associated
FIGURE 2. Overall Survival (ITT).
TABLE 4. Number of Patients with Adverse Events Related
to TG4010 According to the Investigators and Reported in
More Than 5% of the Patients
AEs N % (N/65)
Fatigue 9 13.8
Injection site reaction NOS 9 13.8




Journal of Thoracic Oncology • Volume 3, Number 7, July 2008 Study of Tg4010 in Patients with Stage III/IV NSCLC
Copyright © 2008 by the International Association for the Study of Lung Cancer 741
antigen, in this case with TG4010 targeting MUC1, improves
the results obtained with chemotherapy. The study was ex-
ploratory, with no intended comparison of the 2 Arms, but
rather aimed to investigate 2 ways of combining TG4010
with chemotherapy, either immediately or after an initial
monotherapy with TG4010. The statistical plan was opti-
mized in that the number of patients to be included was
limited in the case that a study arm would not achieve a
sufficient level of efficacy.
The primary end point was chosen to be the response
rate which is usual for the phase II evaluation of a new drug
in oncology but it is clear that an immunotherapy product
may induce biologic changes affecting the course of the
disease in ways having an impact on other parameters than
the objective response such as the disease control, the time to
progression and survival. In this view it was also of impor-
tance to measure the immune response against MUC1 as a
marker of biologic activity of TG4010. Although it is a
serious limitation of the study that only half of the patients
could be assessed for immune response, it is clear from the
data in Figure 3, that patients who have a CD8 T cell
response to MUC1 at some point during the study, were part
of the group of patients with better time to progression and/or
better survival. Interestingly also, MUC1 specific ELISpot in
blood samples taken before therapy was associated with a
better response rate (Table 3), as well as time to progression
and survival (data not shown). However based on the avail-
able data it cannot be stated that TG4010 is the reason of this
observation.
The fact that 49/65 (75.4%) patients were classified
stage IV and PS1 rules out the possibility of an obvious
positive selection bias. The distribution of the patients ac-
cording to the histologic subgroups of NSCLC was also
classic, therefore the study population is considered represen-
tative of the studied pathology and disease stage.
MUC1 expression on NSCLC is associated with a
poorer prognosis due to several properties conferred by
MUC1 to the tumor cells: increased capability to metastasize,
reduced sensitivity to chemotherapy and specially to cispla-
tine.26,27 The fact that the study population was selected for
having MUC1 expressing tumors can therefore be interpreted
as a possible negative selection bias. The safety profile of
TG4010 with injection site reactions, flu-like symptoms and
fatigue as main related adverse effects is in accordance with
what is anticipated to be observed with a live attenuated viral
vaccine and with the known side effects of vaccination with
MVA.17 The combination of AE from TG4010, the chemo-
therapy and the disease can make difficult the assessment of
the relationship to the study drug for some symptoms such as
fatigue. A more precise evaluation of the safety of TG4010
will be provided by a larger on-going randomized study
allowing the comparison of 2 populations with the same
disease and chemotherapy but differing for the administration
or not of TG4010. The fact that the great majority of the AE
related to TG4010 were of mild or moderate intensity allows
the use of this product in patients with an advanced disease
treated with chemotherapy. In no patient did the combination
of TG4010 and chemotherapy need be stopped due to inter-
actions between the 2 products, demonstrating the feasibility
of this combination. The fact that the MVA is nonreplicative
explains why even in the case of patients with chemotherapy
induced neutropenia the injection of the vaccine did not
induce exacerbated injection site manifestations.
The response rate observed in the immediate combina-
tion, 14 out of the first 33 evaluable patients, is higher than the
11/33 responding patients which was the statistical threshold to
be achieved for considering TG4010 to be further developed in
this indication. The response rate established after central read-
ing was more stringent as the same evaluation at the investigator
level. In Arm 2, monotherapy with TG4010 followed by com-
bination with chemotherapy, the response rate in combination, 2
out of 14 evaluable, was not sufficient for moving to the second
stage of the statistical plan.
In the case of targeted therapies and immunotherapy
other endpoints than response rate may be of more impor-
FIGURE 3. TTP and OS according to cellular immune
response against MUC1 for the whole study population. Pa-
tients with () or without (——) MUC1-specific ELISpot
at any timepoint. A: Time to progression. B: Overall survival.
o  complete data,   censored. Differences between the
2 populations are statistically significant with A: p  0.025
and B: p  0.001.
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tance as these new approaches are considered to induce
stabilizations or reduction in the progression rate more fre-
quently than tumor shrinkage.28 Overall survival measured at,
respectively, 12.7 and 14.9 months in Arms 1 and 2 compares
favorably to those which have been reported in the literature
with the same chemotherapy regimen used alone.29,30–31 Even
if observed in a smaller cohort of patients, the median TTP
and OS in Arm 2 are consistent with the results obtained in
Arm 1. These results, in addition, have been obtained in a
population with MUC1 expressing tumors believed to be of
worse prognosis as compared with unselected advanced
NSCLC. Nineteen patients stable or responding after 6 cycles
of chemotherapy continued to be administered with TG4010
as a maintenance therapy and up to 16 months of adminis-
tration. These observations support an administration of
TG4010 beyond chemotherapy as a maintenance therapy.
Another MUC1 directed immunotherapy, Stimuvax, after
encouraging phase IIb results is under clinical development
as a maintenance therapy in NSCLC patients with a Stage
IIIA disease stable or in response after chemotherapy-radio-
therapy.32
The overall hypothesis raised by this study is that
TG4010 may improve the outcome of advanced NSCLC
patients with a MUC1 positive tumor treated with chemo-
therapy. Other products have been or are being developed
with the aim of improving the results of first line chemother-
apy in NSCLC. Small inhibitory molecules like gefitinib
(Iressa) or erlotinib (Tarceva) have failed to demonstrate an
improvement in this setting33,34 while a monoclonal antibody,
Bevacizumab (Avastin) has demonstrated a survival advan-
tage despite some severe adverse events like bleeding or
thrombo-embolism.35 To demonstrate that TG4010 improves
the outcome of patients with advanced MUC1 positive
NSCLC receiving first line chemotherapy a further study has
been initiated evaluating the outcome of this population of
patients receiving a first line chemotherapy alone or in com-
bination with TG4010. This study should provide information
on the benefit and risks of combining TG4010 as a specific
cancer directed immunotherapy with first line chemotherapy
in this indication.
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